about
Influence of physical properties of carrier on the performance of dry powder inhalersTargeted and effective photodynamic therapy for cancer using functionalized nanomaterialsExosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challengesProgress and perspectives on targeting nanoparticles for brain drug delivery.Charge-reversal nanoparticles: novel targeted drug delivery carriersThe role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseasesArtemisinin anti-malarial drugs in ChinaInjected nanocrystals for targeted drug deliveryTargeting hyaluronan for the treatment of pancreatic ductal adenocarcinomaDirect anti-HCV agents5'-Monophosphate-activated protein kinase (AMPK) improves autophagic activity in diabetes and diabetic complicationsRegulation of AMP-activated protein kinase by natural and synthetic activatorsAn Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitorsMechanism-based design of 2,3-benzodiazepine inhibitors for AMPA receptorsPharmacological intervention of HIV-1 maturationFundamental aspects of solid dispersion technology for poorly soluble drugsBrain tumor-targeted drug delivery strategiesEmerging role of microRNAs in lipid metabolismRecent advances in the study of (-)clausenamide: chemistry, biological activities and mechanism of actionHydrogen sulfide prodrugs-a reviewNanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatmentThe pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapyCurrent developments in pharmacological therapeutics for chronic constipationThe Ikaros family of zinc-finger proteinsPBPK modeling and simulation in drug research and developmentExposure to inorganic arsenic can lead to gut microbe perturbations and hepatocellular carcinomaFatty liver diseases, bile acids, and FXRMicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeuticsA brief history of the discovery of PXR and CAR as xenobiotic receptorsThe fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015New techniques of on-line biological sample processing and their application in the field of biopharmaceutical analysisRenal drug transporters and their significance in drug-drug interactionsIsoniazid metabolism and hepatotoxicityInsights into CYP2B6-mediated drug-drug interactionsAn update on the role of intestinal cytochrome P450 enzymes in drug dispositionPXR variants: the impact on drug metabolism and therapeutic responsesCrosstalk of HNF4α with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipidsNew small-molecule drug design strategies for fighting resistant influenza AAlectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
P1433
Q26740570-05482653-9285-4D64-913C-242BA770DF3BQ26740575-1DDA8CBD-4972-474B-9F82-FC7696E5E005Q26740577-7B1DEE5F-B6A7-47DC-807A-7E1EC4E50EA2Q26740580-C4E15359-6E56-4422-9FCE-2FF65C5D6580Q26740583-48C9B21B-7E5C-4182-91A9-F4D7CBB01672Q26749818-60E56A0F-5BB0-4C73-8064-55DDB0777797Q26752394-5E8A51EE-13E4-4A1B-97EC-174DCFBCDD69Q26752396-5D38EDA3-238F-468F-9DC6-3FF3E6715702Q26752400-6EF79EC3-C2A3-4ED0-9407-BCEC33C44EFEQ26767329-16BAC24D-C2EB-4E07-8B23-FF2F527714CDQ26767331-234CDEEE-49D8-4C03-9285-B114806E0153Q26767334-E1866AA5-2FF7-4DEC-8FD2-9663D8814922Q26771734-CA2F5E5D-2347-4F83-806D-34EB7FF55212Q26771736-D2CCCA2E-CF24-4471-8A04-71F639A159B5Q26771738-C432B884-17DF-44AB-8CF0-F3B19C20DBEAQ26771739-7B8A9555-242F-4458-A785-1F39ADD64387Q26822873-AF0D5586-5FAC-49BB-A271-303EB308D421Q26829741-25DE5D77-0F52-4DE6-9AF4-5E3C9FFD740EQ26852591-0778A5CE-480A-42A8-BC52-AB5AD09AC5DDQ26861545-31A18225-2365-487F-83E9-72E447A04482Q26865084-08376AE5-6C88-4D0D-9E4D-686DC076D7F8Q26866566-633E2082-5728-4C5C-B04F-D0B4181D2FF5Q27004672-F589E8CD-BB62-405C-9D11-412711A8F1C7Q27025474-41D68330-CF86-4FC9-BF38-124981F7BC9FQ28066194-97D0ECC7-FA62-4546-9AE6-E356E652BCA2Q28066513-DD697BC4-5C81-41DB-9128-EC4C99EB5F63Q28066679-8CEF3887-2944-44A1-8436-30502E063E64Q28068199-E64F93D5-F33F-4237-A8C9-4842B5A500D7Q28068338-D62D9944-87A1-43A4-934A-BDF71D0CFA9AQ28069376-2AFC0321-34A2-4AF4-B49B-1185C28EC164Q28069442-A67A6993-56C6-4C16-B25B-D37FFB307762Q28069797-BB5E22D8-D3DB-4B0E-99C0-F25569580815Q28071292-AAACAAD0-8504-451F-9558-B06D76E97358Q28076859-9244E01D-E431-42EA-B884-6BE57952B8DEQ28078857-C21B33B9-BDCA-408A-AC8B-E920CA3EF170Q28079725-715986B7-A578-4EF0-822E-FA0F0D8B5519Q28080023-ACA2A82A-0A29-4D6F-B905-7E6479BEBD9AQ28080239-DDCCED6E-D5F0-4F08-9F63-FDED7973C740Q28080554-F7EA5DC4-D678-43A4-B33F-D04AFD6BD4F2Q28081606-89C6DE3D-4C32-4638-9509-A78457816DF2
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Elsevier
@nl
wissenschaftliche Fachzeitschrift
@de
name
Acta pharmaceutica Sinica B
@ast
Acta pharmaceutica Sinica B
@en
Acta pharmaceutica Sinica B
@es
Acta pharmaceutica Sinica B
@it
Acta pharmaceutica Sinica B
@pl
Acta pharmaceutica Sinica nstitute of Materia Medica. B /
@nl
type
label
Acta pharmaceutica Sinica B
@ast
Acta pharmaceutica Sinica B
@en
Acta pharmaceutica Sinica B
@es
Acta pharmaceutica Sinica B
@it
Acta pharmaceutica Sinica B
@pl
Acta pharmaceutica Sinica nstitute of Materia Medica. B /
@nl
altLabel
Acta Pharmaceutica Sinica B
@en
prefLabel
Acta pharmaceutica Sinica B
@ast
Acta pharmaceutica Sinica B
@en
Acta pharmaceutica Sinica B
@es
Acta pharmaceutica Sinica B
@it
Acta pharmaceutica Sinica B
@pl
Acta pharmaceutica Sinica nstitute of Materia Medica. B /
@nl
P31
P3181
P1055
P1156
20700195026
P123
P236
P3181
P5115
P5963
acta-pharmaceutica-sinica-b